PURPOSE: To determine if there is significant symptomatology in women with heterozygous alpha-galactosidase mutations. METHODS: Data from medical records of the 44 heterozygous females followed at Cedars-Sinai Medical Center were compiled and analyzed for symptoms of Fabry disease. Quality of life data were also analyzed. RESULTS: Seventy-six percent were referred due to an affected male relative; 76% reported acroparesthesias as their first symptom. A mean of 15.7 years elapsed from onset of first symptoms to the diagnosis. Quality of life, measured by the SF-36 survey, was globally reduced. Pain affected mood and enjoyment of life. Central/peripheral nervous, cardiopulmonary, and renal system manifestations of Fabry disease were present far above that predicted for random X-inactivation of the normal allele. Fatigue, present in 59%, was associated with reduced maximum oxygen consumption (P=0.049); exercise intolerance, present in 83%, was associated with reduced maximal heart rate during exercise testing (P=0.0089). Women diagnosed via family history experienced more angina (P=0.035), decreased vibration sense (P=0.026), and had a worse percentage predicted FEF25-75 (P=0.037) compared to women diagnosed because of symptoms. CONCLUSIONS: This study indicates that the asymptomatic female carrier of Fabry disease is the exception, not the rule: heterozygotes suffer from significant multisystemic disease and reduced quality of life and must be monitored and treated accordingly.
PURPOSE: To determine if there is significant symptomatology in women with heterozygous alpha-galactosidase mutations. METHODS: Data from medical records of the 44 heterozygous females followed at Cedars-Sinai Medical Center were compiled and analyzed for symptoms of Fabry disease. Quality of life data were also analyzed. RESULTS: Seventy-six percent were referred due to an affected male relative; 76% reported acroparesthesias as their first symptom. A mean of 15.7 years elapsed from onset of first symptoms to the diagnosis. Quality of life, measured by the SF-36 survey, was globally reduced. Pain affected mood and enjoyment of life. Central/peripheral nervous, cardiopulmonary, and renal system manifestations of Fabry disease were present far above that predicted for random X-inactivation of the normal allele. Fatigue, present in 59%, was associated with reduced maximum oxygen consumption (P=0.049); exercise intolerance, present in 83%, was associated with reduced maximal heart rate during exercise testing (P=0.0089). Women diagnosed via family history experienced more angina (P=0.035), decreased vibration sense (P=0.026), and had a worse percentage predicted FEF25-75 (P=0.037) compared to women diagnosed because of symptoms. CONCLUSIONS: This study indicates that the asymptomatic female carrier of Fabry disease is the exception, not the rule: heterozygotes suffer from significant multisystemic disease and reduced quality of life and must be monitored and treated accordingly.
Authors: Marcella A Wozniak; Steven J Kittner; Stanley Tuhrim; John W Cole; Barney Stern; Mark Dobbins; Marie E Grace; Irina Nazarenko; Robert Dobrovolny; Eric McDade; Robert J Desnick Journal: Stroke Date: 2009-12-10 Impact factor: 7.914
Authors: Dawn Alyssia Laney; Daniel J Gruskin; Paul M Fernhoff; Joseph F Cubells; Opal Y Ousley; Heather Hipp; Ami J Mehta Journal: J Inherit Metab Dis Date: 2010-01-20 Impact factor: 4.982
Authors: Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick Journal: Nephrol Dial Transplant Date: 2009-02-13 Impact factor: 5.992
Authors: Helena Poupetová; Jana Ledvinová; Linda Berná; Lenka Dvoráková; Viktor Kozich; Milan Elleder Journal: J Inherit Metab Dis Date: 2010-05-20 Impact factor: 4.982